The pharmaceutical and biotech industry is changing. We have already seen a shift from small molecule-based drugs to more complex biologics, but now a range of more advanced therapies are entering the scene such as cell therapies or virus-based drugs in oncolytic vaccines for use in gene therapies. These more complex and specialised therapies are offering incredible new therapeutic potential, but also come with their own unique set of challenges. Phil Morton at Albumedix Technology Group clarifies how these innovative types of therapies can be addressed by a known and established excipient: albumin.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/10/The-Power-of-Recombinant-Human-Albumin.pdf” width=”100%” height=”900px” style=”border:0;”]